Lexaria Bioscience (LEXX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience is set to explore a new frontier with its DehydraTECH-liraglutide, an oral version of the multi-billion dollar drug liraglutide, following promising results in animal studies. The company plans a human pilot study to compare its formulation against the injectable Saxenda® and aims to unlock potential revenue opportunities in the GLP-1 drug market. If successful, this could lead to further trials and expansion within this lucrative sector.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.